ArticleEpilepsy & behavior reports2026
Feasibility and impact of virtual reality exposure therapy on epilepsy-specific anxiety: Phase 3 of the AnxEpiVR pilot clinical trial.
Article in Epilepsy & behavior reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with epilepsy (PwE) commonly experience interictal anxiety related to their epilepsy and seizures. However, therapeutic interventions have received minimal investigation. This study was the third phase of the "AnxEpiVR" pilot that examined the feasibility and effectiveness of a novel virtual reality exposure therapy (VR-ET) program to treat epilepsy-specific (ES) interictal anxiety in PwE. Participants (N = 5) completed the Epilepsy Anxiety Survey Instrument (EASI), Perceived Stress Scale, Igroup Presence Questionnaire, System Usability Scale, and an adapted version of the diagnostic protocol that Hingray et al. (2019) proposed. They also participated in a semi-structured interview. Participants were assigned to a personally relevant VR-ET scenario (dinner party, shopping mall, or a subway station/train). Over 12 to 14 days within a 14-day period, participants engaged in the VR-ET intervention, progressing through an individualized hierarchy of exposures. Preliminary findings suggest promising feasibility of VR-ET and high tolerability, achieving a 100% completion rate. The EASI scores showed that two of the four participants who scored above the cut-off for a probable anxiety disorder before VR-ET (brief EASI ≥ 7) scored below the cut-off after VR-ET (brief EASI < 7). Subjective reports of the VR-ET's impact supported the intervention's potential for reducing ES-interictal anxiety. This trial represents the inaugural use of VR-ET as a potential remote intervention for ES-interictal anxiety. Moreover, these findings support the feasibility of conducting larger clinical trials to further evaluate and to validate VR-ET as a therapeutic tool for managing interictal anxiety in PwE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.